These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 32407047)
1. Post-heart transplantation lymphoproliferative diseases (PTLDs) and the diagnostic role of [18f] FDG-PET/CT. Sica A; DE Rimini ML; Sagnelli C; Casale B; Spada A; Reginelli A; Amarelli C; Maiello C; Belfiore MP; Creta M; Ciccozzi M; Sagnelli E; Troiani T; Cappabianca S Minerva Med; 2021 Jun; 112(3):338-345. PubMed ID: 32407047 [TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease. Bianchi E; Pascual M; Nicod M; Delaloye AB; Duchosal MA Transplantation; 2008 Mar; 85(5):707-12. PubMed ID: 18337664 [TBL] [Abstract][Full Text] [Related]
3. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709 [TBL] [Abstract][Full Text] [Related]
4. Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [18F]-FDG-PET(/CT) in initial staging and therapy monitoring. von Falck C; Maecker B; Schirg E; Boerner AR; Knapp WH; Klein C; Galanski M Eur J Radiol; 2007 Sep; 63(3):427-35. PubMed ID: 17293073 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield. Montes de Jesus FM; Kwee TC; Kahle XU; Nijland M; van Meerten T; Huls G; Dierckx RAJO; Rosati S; Diepstra A; van der Bij W; Verschuuren EAM; Glaudemans AWJM; Noordzij W Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):529-536. PubMed ID: 31444510 [TBL] [Abstract][Full Text] [Related]
7. The value of 18F-FDG PET in pediatric patients with post-transplant lymphoproliferative disorder at initial diagnosis. Vali R; Punnett A; Bajno L; Moineddin R; Shammas A Pediatr Transplant; 2015 Dec; 19(8):932-9. PubMed ID: 26515450 [TBL] [Abstract][Full Text] [Related]
8. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD. Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392 [TBL] [Abstract][Full Text] [Related]
9. Role of Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569 [TBL] [Abstract][Full Text] [Related]
10. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979 [TBL] [Abstract][Full Text] [Related]
11. Roles of F-18-Fluoro-2-Deoxy-Glucose PET/Computed Tomography Scans in the Management of Post-Transplant Lymphoproliferative Disease in Pediatric Patient. Xu YF; Yang JG PET Clin; 2020 Jul; 15(3):309-319. PubMed ID: 32498987 [TBL] [Abstract][Full Text] [Related]